.. Villes-correspondantes, Liste des codes postaux, Annexe, vol.5, p.69

R. Hart, L. Pearce, and M. Aguilar, Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation, Annals of Internal Medicine, vol.146, issue.12, pp.857-67, 2007.
DOI : 10.7326/0003-4819-146-12-200706190-00007

M. Ezekowitz, S. Bridgers, and K. James, Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation, New England Journal of Medicine, vol.327, issue.20, pp.1406-1418, 1992.
DOI : 10.1056/NEJM199211123272002

D. Singer, R. Hughes, and D. Gress, The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: The BAATAF Study):1567?73. 4. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group, Am Heart J. déc Lancet. 20 nov, vol.124342, issue.68882, pp.1255-62, 1992.

P. Petersen, G. Boysen, and J. Godtfredsen, PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study, The Lancet, vol.333, issue.8631, pp.175-184, 1989.
DOI : 10.1016/S0140-6736(89)91200-2

C. Laget, Évaluation de l'équilibre des AVK en post-hospitalisation chez des sujets âgés traités pour une FA : FAREMBOL-AMBU 1re partie. Étude rétrospective sur un territoire géographique déterminé de la région Aquitaine [médicale], Bordeaux, vol.2, 2014.

A. Go, E. Hylek, and K. Phillips, Prevalence of Diagnosed Atrial Fibrillation in Adults, JAMA, vol.285, issue.18, pp.2370-2375, 2001.
DOI : 10.1001/jama.285.18.2370

R. Roller, B. Iglseder, and P. Dovjak, Oral anticoagulation and risk of bleeding in elderly patients -the aspect of polypharmacy]-12):270?5. 9. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators, Wien Med Wochenschr juin Arch Intern Med. 26 févr, vol.160156, issue.114, pp.409-425, 1946.

E. Hylek, D. Antonio, J. Evans-molina, and C. , Translating the Results of Randomized Trials into Clinical Practice: The Challenge of Warfarin Candidacy Among Hospitalized Elderly Patients With Atrial Fibrillation, Stroke, vol.37, issue.4, pp.1075-80, 2006.
DOI : 10.1161/01.STR.0000209239.71702.ce

L. Tulner, J. Van-campen, and I. Kuper, Reasons for Undertreatment with Oral Anticoagulants in Frail Geriatric Outpatients with Atrial Fibrillation, Drugs & Aging, vol.290, issue.7, pp.39-50, 2010.
DOI : 10.2165/11319540-000000000-00000

B. Gage, A. Waterman, and W. Shannon, Validation of Clinical Classification Schemes for Predicting Stroke, JAMA, vol.285, issue.22, pp.2864-70, 2001.
DOI : 10.1001/jama.285.22.2864

A. Fugh-berman, Herb-drug interactions, The Lancet, vol.355, issue.9198, pp.134-142, 2000.
DOI : 10.1016/S0140-6736(99)06457-0

G. Palareti, N. Leali, and S. Coccheri, Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT), The Lancet, vol.348, issue.9025, pp.423-431, 1996.
DOI : 10.1016/S0140-6736(96)01109-9

C. Heneghan, P. Alonso-coello, and J. Garcia-alamino, Self-monitoring of oral anticoagulation: a systematic review and meta-analysis, The Lancet, vol.367, issue.9508, pp.404-415, 2006.
DOI : 10.1016/S0140-6736(06)68139-7

G. Dolan, L. Smith, and S. Collins, Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature, Current Medical Research and Opinion, vol.24, issue.5, pp.1459-72, 2008.
DOI : 10.1185/030079908X297349

D. Poli, E. Antonucci, and R. Marcucci, Risk of bleeding in very old atrial fibrillation patients on warfarin: Relationship with ageing and CHADS2 score, Thrombosis Research, vol.121, issue.3, pp.347-52, 2007.
DOI : 10.1016/j.thromres.2007.05.014

D. Poli, E. Antonucci, and E. Grifoni, Bleeding Risk During Oral Anticoagulation in Atrial Fibrillation Patients Older Than 80 Years, Journal of the American College of Cardiology, vol.54, issue.11, pp.999-1002, 2009.
DOI : 10.1016/j.jacc.2009.05.046

A. Cafolla, M. Campanelli, and E. Baldacci, Oral anticoagulant therapy in Italian patients 80??yr of age or older with atrial fibrillation: a pilot study of low vs. standard PT/INR targets, European Journal of Haematology, vol.171, issue.1, pp.81-87, 2012.
DOI : 10.1111/j.1600-0609.2012.01786.x

G. Palareti, J. Hirsh, and C. Legnani, Oral Anticoagulation Treatment in the Elderly, Archives of Internal Medicine, vol.160, issue.4, pp.470-478, 2000.
DOI : 10.1001/archinte.160.4.470

E. Hylek, C. Evans-molina, and C. Shea, Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation, Circulation, vol.115, issue.21, pp.2689-96, 2007.
DOI : 10.1161/CIRCULATIONAHA.106.653048

L. Poller, M. Keown, and S. Ibrahim, An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage, Journal of Thrombosis and Haemostasis, vol.69, issue.6, pp.935-978, 2008.
DOI : 10.1056/NEJM199507063330103

J. Hirsh, J. Dalen, and D. Anderson, Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range, Chest, vol.119, issue.1, pp.8-21, 2001.
DOI : 10.1378/chest.119.1_suppl.8S

D. Poli, E. Antonucci, and A. Lombardi, Low incidence of hemorrhagic complications of oral anticoagulant therapy in patients with atrial fibrillation in the daily practice of an anticoagulation clinic, Ital Heart J Off J Ital Fed Cardiol. janv, vol.4, issue.1, pp.44-51, 2003.

C. Morgan, P. Mcewan, and A. Tukiendorf, Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control, Thrombosis Research, vol.124, issue.1, pp.37-41, 2009.
DOI : 10.1016/j.thromres.2008.09.016

C. Ruff, R. Giugliano, and E. Braunwald, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, The Lancet, vol.383, issue.9921, pp.955-62, 2014.
DOI : 10.1016/S0140-6736(13)62343-0

URL : https://hal.archives-ouvertes.fr/hal-00935589

M. Haim, M. Hoshen, and O. Reges, Prospective National Study of the Prevalence, Incidence, Management and Outcome of a Large Contemporary Cohort of Patients With Incident Non?Valvular Atrial Fibrillation Disponible sur, J Am Heart Assoc Cardiovasc Cerebrovasc Dis, vol.4, issue.1

J. Heeringa, D. Kuip, . Van-der, and A. Hofman, Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study, European Heart Journal, vol.27, issue.8, pp.949-53, 2006.
DOI : 10.1093/eurheartj/ehi825

M. Marcucci, G. Lip, and R. Nieuwlaat, Stroke and Bleeding Risk Co-distribution in Real-world Patients with Atrial Fibrillation: The??Euro Heart Survey, The American Journal of Medicine, vol.127, issue.10, pp.979-86, 2014.
DOI : 10.1016/j.amjmed.2014.05.003

P. Gallego, V. Roldán, and F. Marin, SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation, The American Journal of Medicine, vol.127, issue.11, pp.1083-1091, 2014.
DOI : 10.1016/j.amjmed.2014.05.023

G. Lip, K. Haguenoer, and C. Saint-etienne, Relationship of the SAMe-TT2 R2 Score to Poor-Quality Anticoagulation, Stroke, Clinically Relevant Bleeding, and Mortality in Patients With Atrial Fibrillation, Chest, vol.146, issue.3, pp.719-745, 2014.
DOI : 10.1378/chest.13-2976

. Loi, portant diverses dispositions d'adaptation au droit communautaire dans le domaine de la lutte contre les discriminations, 2008.

O. Reilly, R. Trager, W. Rettie, and A. , Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans, Clinical Pharmacology and Therapeutics, vol.42, issue.3, pp.290-294, 1987.
DOI : 10.1038/clpt.1987.149

J. Moroney, C. Tseng, and M. Paik, Treatment for the Secondary Prevention of Stroke in Older Patients: The Influence of Dementia Status, Journal of the American Geriatrics Society, vol.26, issue.7, pp.824-833, 1999.
DOI : 10.1111/j.1532-5415.1999.tb03839.x

M. Debray, E. Pautas, and P. Couturier, Anticoagulation orale en pratique g??riatrique, La Revue de M??decine Interne, vol.24, issue.2, pp.107-124, 2003.
DOI : 10.1016/S0248-8663(02)00020-6

L. Gottlieb and S. Salem-schatz, Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med. 12 sept, pp.1945-53, 1994.

A. Evans and L. Kalra, Are the Results of Randomized Controlled Trials on Anticoagulation in Patients With Atrial Fibrillation Generalizable to Clinical Practice?, Archives of Internal Medicine, vol.161, issue.11, pp.1443-1450, 2001.
DOI : 10.1001/archinte.161.11.1443

L. Wallentin, S. Yusuf, and M. Ezekowitz, Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial, The Lancet, vol.376, issue.9745, pp.975-83, 2010.
DOI : 10.1016/S0140-6736(10)61194-4

L. Poller, M. Keown, and S. Ibrahim, A multicentre randomised clinical endpoint study of parma 5 computer-assisted oral anticoagulant dosage, British Journal of Haematology, vol.90, issue.suppl, pp.274-83, 2008.
DOI : 10.1111/j.1365-2141.2008.07337.x

L. Poller, M. Keown, and S. Ibrahim, A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program, Thrombosis and Haemostasis, vol.101, issue.3, pp.487-94, 2009.
DOI : 10.1160/TH08-10-0664

F. Ferrando and Y. Mira, Effective and Safe Management of Oral Anticoagulation Therapy in Patients Who Use the Internet-Accessed Telecontrol Tool SintromacWeb, interactive Journal of Medical Research, vol.4, issue.2, p.10, 2015.
DOI : 10.2196/ijmr.3610

J. Prochaska, S. Göbel, and K. Keller, Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service ??? results from the prospective, multi-center, observational cohort study thrombEVAL, BMC Medicine, vol.349, issue.1, p.14, 2015.
DOI : 10.1136/bmj.g4517

C. Manotti, M. Moia, and G. Palareti, Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment)

A. Cafolla, L. Manisco, and E. Baldacci, Effectiveness and Safety of Therapy with Vitamin K Antagonists in Italian Patients Aged 80??Years or Older: a Multicentre Retrospective Study Comparing the Zeus Algorithm with the PARMA Algorithm or Manual Therapy, Drugs & Aging, vol.63, issue.3, pp.235-276, 2015.
DOI : 10.1007/s40266-015-0247-z

A. Cafolla, R. Melizzi, and E. Baldacci, ???Zeus??? a new oral anticoagulant therapy dosing algorithm : A cohort study, Thrombosis Research, vol.128, issue.4, pp.325-355, 2011.
DOI : 10.1016/j.thromres.2011.04.012

I. Dimberg, B. Grzymala-lubanski, and A. Hägerfelth, Computerised assistance for warfarin dosage ??? Effects on treatment quality, European Journal of Internal Medicine, vol.23, issue.8, pp.742-746, 2012.
DOI : 10.1016/j.ejim.2012.07.011

A. Papaioannou, C. Kennedy, and G. Campbell, A team-based approach to warfarin management in long term care: A feasibility study of the MEDeINR electronic decision support system, BMC Geriatrics, vol.14, issue.1, p.38, 2010.
DOI : 10.1023/A:1022018422237

Y. Van-leeuwen, E. Rombouts, and C. Kruithof, Improved control of oral anticoagulant dosing: a randomized controlled trial comparing two computer algorithms, Journal of Thrombosis and Haemostasis, vol.69, issue.8, pp.1644-1653, 2007.
DOI : 10.2307/2529712

L. Poller, M. Keown, and S. Ibrahim, An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage, Journal of Thrombosis and Haemostasis, vol.69, issue.6, pp.935-978, 2008.
DOI : 10.1056/NEJM199507063330103

L. Poller, C. Shiach, and P. Maccallum, Multicentre randomised study of computerised anticoagulant dosage, The Lancet, vol.352, issue.9139, pp.1505-1514, 1998.
DOI : 10.1016/S0140-6736(98)04147-6

S. Jowett, S. Bryan, and L. Poller, The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study, Journal of Thrombosis and Haemostasis, vol.11, issue.Suppl, pp.1482-90, 2009.
DOI : 10.1111/j.1538-7836.2009.03508.x

B. Maillet and H. Maisonneuve, [Long-life learning for medical specialists doctors in Europe: CME, DPC and qualification]. Presse Médicale Paris Fr, avr, vol.40, issue.4, 1983.

/. Justification, Les patients en FA et présentant des facteurs de risques thrombo-emboliques (CHA2DS2VASC>1) sont éligibles au traitement anticoagulant par AVK [1]. Il est reconnu que les anti-vitamines K (AVK) sont plus efficaces que l'aspirine dans la prévention des accidents vasculaires ischémiques d'origine thrombo-embolique

. Dans-leur-Étude and N. Claes, ont montré que la mise à disposition d'outils, auprès de médecins généralistes sur l'utilisation des AVK permet une amélioration du TTR quels que soient les moyens d'intervention c'est-à-dire le rappel simple des recommandations au début de l'étude, ou l'évaluation répétée des pratiques, l'utilisation d'un appareil d'auto mesure pour contrôler les INR, ou enfin l'utilisation d'un logiciel informatique d'aide à l'adaptation des posologies

R. Hart, L. Pearce, and M. Aguilar, Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation, Annals of Internal Medicine, vol.146, issue.12, pp.857-67, 2007.
DOI : 10.7326/0003-4819-146-12-200706190-00007

I. Ogilvie, N. Newton, S. Welner, W. Cowell, and G. Lip, Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review, The American Journal of Medicine, vol.123, issue.7, pp.638-683, 2010.
DOI : 10.1016/j.amjmed.2009.11.025

P. Wolf, R. Abbott, and W. Kannel, Atrial fibrillation as an independent risk factor for stroke: the Framingham Study, Stroke, vol.22, issue.8, pp.983-991, 1991.
DOI : 10.1161/01.STR.22.8.983

. Afssaps, Suivi biologique du traitement par antivitamine K, 2003.

. Ansell, Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM), Journal of Thrombosis and Thrombolysis, vol.335, issue.Suppl, pp.83-91, 2007.
DOI : 10.1007/s11239-006-9022-7

F. Rosendaal, S. Cannegieter, F. Van-der-meer, and E. Briet, A method to determine the optimal intensity of oral anticoagulant therapy, Thromb Haemost, vol.69, issue.3, pp.236-245, 1993.

Y. Wan, C. Heneghan, R. Perera, N. Roberts, J. Hollowell et al., Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial Fibrillation: A Systematic Review, Circulation: Cardiovascular Quality and Outcomes, vol.1, issue.2, pp.84-91, 2008.
DOI : 10.1161/CIRCOUTCOMES.108.796185

N. Claes, F. Buntinx, J. Vijgen, J. Arnout, J. Vermylen et al., The Belgian Improvement Study on Oral Anticoagulation Therapy: a randomized clinical trial, European Heart Journal, vol.26, issue.20, 2005.
DOI : 10.1093/eurheartj/ehi327